Media coverage about Mersana Therapeutics (NASDAQ:MRSN) has trended positive this week, Accern reports. Accern rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Mersana Therapeutics earned a media sentiment score of 0.38 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 47.2411719781565 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Mersana Therapeutics (MRSN) opened at $18.78 on Friday. Mersana Therapeutics has a 1-year low of $12.71 and a 1-year high of $21.01.
Mersana Therapeutics (NASDAQ:MRSN) last announced its earnings results on Thursday, November 9th. The company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.13. The business had revenue of $6.27 million during the quarter, compared to analyst estimates of $3.93 million. research analysts predict that Mersana Therapeutics will post -2.9 EPS for the current fiscal year.
Mersana Therapeutics Company Profile
Mersana Therapeutics, Inc is a United States-based biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs). The Company focuses on advancing a pipeline of targeted oncology therapeutics leveraging its Fleximer immunoconjugate technology. The Fleximer platform allows it to design ADCs with specific properties and manage the drug’s chances of attacking cancers.
Receive News & Ratings for Mersana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.